氨酸丰富的血蛋白质组在阿尔茨海默氏病中发生显著变化
Qi Guo1,2,3, Lingyan Ping1,2,3, Eric B Dammer1,2,3
1Department of Biochemistry, School of Medicine, Emory School of Medicine, 505J Whitehead Biomedical Research Building, 615 Michael St, Atlanta, GA, 30322, USA.
Molecular neurodegeneration
|October 8, 2024
概括
这项研究开发了一种新方法来检测血中的肝素结合蛋白,找到一个由五种蛋白组成的小组,可以帮助诊断阿尔茨海默病 (AD) 并与现有生物标志物结合时改善检测.
科学领域:
- 蛋白质组学是指蛋白质组学.
- 生物标志物发现发现
- 神经退行性疾病 神经退行性疾病
背景情况:
- 肝素结合蛋白 (HBPs) 与阿尔茨海默氏症 (AD) 病理学有关.
- 在血中检测HBPs是用标准方法具有挑战性的.
研究的目的:
- 开发一种方法来丰富和检测人体血中的HBPs.
- 为了将血HBP概况与AD生物标志物和大脑病理相关联.
主要方法:
- 在AD和对照个体的血上使用了氨酸亲和染色学和双重质量标记质量谱学 (TMT-MS).
- 与脑脊液 (CSF) 和血AD生物标志物 (Aβ,tau,pTau181) 的相关蛋白质概况.
- 将血蛋白质组的变化与AD脑蛋白质组网络进行比较.
主要成果:
- 成功丰富了HBPs,并从血中耗尽了丰富的蛋白质.
- 鉴定了2865种蛋白质,其中一些显示大脑和血之间的一致变化.
- 一个由五种血蛋白组成的小组将AD与对照区分开来 (AUC=0.85).
- 组合面板与血pTau181改善了AD分类 (AUC=0.98).
结论:
- 与TMT-MS相结合的氨酸亲和丰富剂有效检测血中的AD相关蛋白质.
- 血HBP为AD大脑病理生理学提供了宝贵的见解.
- 鉴定的蛋白质面板显示了作为AD的诊断工具的潜力.
相关概念视频
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Anticoagulant Drugs: Low-Molecular-Weight Heparins
633
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
633
Alzheimer's Disease: Treatment
166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166


